한글목차

Seres therapeutics가 개발중인 SER-109는 클로스트리듐 디피실 감염의 재발을 억제하는 최초의 임상용 경구용 마이크로바이옴 치료제가 될 수 있습니다. 인간 임상결과에 기반한 상재균의 다기능성 컨소시엄으로, 항생제 투여 후 경구투여합니다.

SER-109는 건강한 마이크로바이옴에 일반적으로 존재하는 파미큐테스(Firmicutes) 속의 포자를 정제하여 클로스트리듐 디피실(Clostridium difficile)의 수명주기와 질병 발생에 조절적인 역할을 하는 것으로 선택된 것입니다.

앞으로 수년간 클로스트리듐 디피실 감염증 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것으로 예상됩니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근법에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, SER-109의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 클로스트리듐 디피실 감염에 대한 다른 신흥 제품들이 SER-109와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.

주요 7개국의 SER-109 시장에 대해 조사했으며, 시장의 개요와 2023-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 클로스트리듐 디피실 감염증에 대한 SER-109의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 SER-109 시장 평가

• 클로스트리듐 디피실 감염증에 대한 SER-109의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 로스트리지움·디피실 감염증에 대한 SER-109의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"SER-109 Drug Insight and Market Forecast - 2032" report provides comprehensive insights about SER-109 for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the SER-109 for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the SER-109 for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SER-109 market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

SER-109, being developed by Seres therapeutics, is a potential first-in-class investigational oral microbiome therapeutic designed to reduce the recurrence of CDI. It is a multifunctional consortium of commensal bacteria based on human clinical insights and is to be administered orally following antibiotics.

SER-109 is composed of purified firmicutes spores, normally found in healthy microbiome selected for their modulatory role in the life cycle of C. difficile and disease pathogenesis.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SER-109 description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on SER-109 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SER-109 research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SER-109.
• The report contains forecasted sales of SER-109 for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for SER-109 in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SER-109 Analytical Perspective by DelveInsight

In-depth SER-109 Market Assessment

This report provides a detailed market assessment of SER-109 for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

SER-109 Clinical Assessment

The report provides the clinical trials information of SER-109 for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SER-109 dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to SER-109 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SER-109 in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of SER-109 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SER-109 in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of SER-109?
• What is the clinical trial status of the study related to SER-109 in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SER-109 development?
• What are the key designations that have been granted to SER-109 for clostridium difficile infection?
• What is the forecasted market scenario of SER-109 for clostridium difficile infection?
• What are the forecasted sales of SER-109 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SER-109 for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. SER-109 Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SER-109 Market Assessment

• 5.1. Market Outlook of SER-109 in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of SER-109 in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SER-109 in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of SER-109 in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of SER-109 in France for Clostridium difficile infection
  • 5.3.4. Market Size of SER-109 in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of SER-109 in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of SER-109 in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of SER-109 in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options